A practical reference on melanocortin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-21 and is reviewed periodically as new material appears.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
=== Greater Western Sydney === McVeigh then took a head coaching role at the Giants Academy, then transitioned into an assistant coaching role at the Greater Western Sydney Giants from 2015, serving as the defensive coach. McVeigh was appointed as the caretaker senior coach of GWS Giants until the end of the 2022 season, following the mid-season resignation of senior coach Leon Cameron. His first match in charge, in round 10, saw the Giants defeat West Coast by 52 points. McVeigh attracted some criticism from the media after calling out his team's performance against Sydney in Round 20, 2022 but with a mostly unchanged side they would defeat his old club Essendon by 27 points the following week. The club ultimately finished 16th on the ladder with a 6–16 record, its lowest finish since the 2014 AFL season. At the end of the 2022 season, McVeigh was not retained as the senior coach of the GWS Giants and was replaced by Adam Kingsley. On 10 October, McVeigh left the club.
== tRNA biogenesis == In eukaryotic cells, tRNAs are transcribed by RNA polymerase III as pre-tRNAs in the nucleus. RNA polymerase III recognizes two highly conserved downstream promoter sequences: the 5′ intragenic control region (5′-ICR, D-control region, or A box), and the 3′-ICR (T-control region or B box) inside tRNA genes. The first promoter begins at +8 of mature tRNAs and the second promoter is located 30–60 nucleotides downstream of the first promoter. The transcription terminates after a stretch of four or more thymidines.
During Alice in Chains' hiatus, reports of Staley's addiction began to gain widespread circulation in fan and media communities, in part due to changes in his physical condition brought on by prolonged heroin abuse. Alice in Chains regrouped to record Alice in Chains, sometimes referred to as "Tripod" due to the cover featuring a three-legged dog, which was released in November 1995. The album debuted at the top of the U.S. charts, and has since been awarded—along with Facelift and Jar of Flies—double platinum status. With the exceptions of "Grind", "Heaven Beside You", and "Over Now", the lyrics were all written by Staley, making this album his greatest lyrical contribution to the band's catalog. To accompany the album, the band released a home video, The Nona Tapes, but the band lapsed again, failing to complete tours planned in support of the album. When asked about the frustration of not touring to support the record, Cantrell provided some insight into how Staley's addictions led to tensions within the band: "Very frustrating, but we stuck it out. We rode the good times together, and we stuck together through the hard times. We never stabbed each other in the back and spilled our guts and [did] that kind of bullshit that you see happen a lot." "Drugs worked for me for years", Staley told Rolling Stone in February 1996, "and now they're turning against me, now I'm walking through hell and this sucks. I didn't want my fans to think that heroin was cool. But then I've had fans come up to me and give me the thumbs up, telling me they're high.
Sources: en.wikipedia.org
=== Direct Chemical Synthesis === Although the focus has primarily been on enzymatic approaches for overcoming length limitations with oligonucleotide synthesis, a proposed alternative is direct chemical synthesis. Standard oligo-synthesis is done on porous materials, such as controlled pore glass (CPG). However, this environment introduces challenges as sequence length increases. Longer strands take up more space within the pores and limit reagent access, which results in lower coupling efficiency and a greater number of truncated sequences in a solution. One innovative approach includes chemically synthesizing the oligonucleotides on a smooth surface, as opposed to porous material, to improve coupling efficiency while additionally utilizing the purification strategy, catching-by-polymerization (CBP), to selectively isolate full-length oligos in a solution. Performing chemical synthesis on a smooth surface, such as glass wool or glass beads, reduces steric strain and congestion, thus providing alternative solid support benefitting long-oligos.
Although eating tainted beef can lead to New Variant Creutzfeldt-Jakob disease (the human variant of mad-cow disease, bovine spongiform encephalopathy), there is no known case of BSE having been transmitted through collagen products such as gelatine.
Mithridates' father was assassinated by poisoning, according to some at his mother's orders. After this, Mithridates's mother held regency over Pontus until a male heir was of age. Mithridates was in competition with another brother, whom his mother favored, for the throne. Supposedly during his youth he began to suspect plots against him at his mother's orders and was aware of her likely connection with his father's death. He then, supposedly, began to notice pains during his meals, and suspected his mother had ordered small amounts of poison to be added to his food in order to cause his health to deteriorate while avoiding notice of intent to kill him slowly. After other assassination attempts, he fled into the wilderness. While in the wild it is said that he began consuming non-lethal levels of poisons and mixing many into a remedy to make him immune to many poisons. In keeping with most medical practices of his era, Mithridates' anti-poison routines included a religious component supervised by Agari, or Scythian shamans who never left his side.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.